

## CHRNA5 Antibody (Center) Blocking peptide

Synthetic peptide Catalog # BP14006c

### **Specification**

## CHRNA5 Antibody (Center) Blocking peptide - Product Information

Primary Accession

P30532

# CHRNA5 Antibody (Center) Blocking peptide - Additional Information

**Gene ID 1138** 

#### **Other Names**

Neuronal acetylcholine receptor subunit alpha-5, CHRNA5, NACHRA5

### Target/Specificity

The synthetic peptide sequence used to generate the antibody AP14006c was selected from the Center region of CHRNA5. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

### **Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

#### **Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

### **Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

## CHRNA5 Antibody (Center) Blocking peptide - Protein Information

### Name CHRNA5

## **Synonyms NACHRA5**

#### Function

After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.

#### **Cellular Location**

Postsynaptic cell membrane; Multi-pass membrane protein. Cell membrane; Multi-pass membrane protein

# CHRNA5 Antibody (Center) Blocking peptide - Protocols



Provided below are standard protocols that you may find useful for product applications.

## • Blocking Peptides

## CHRNA5 Antibody (Center) Blocking peptide - Images

# CHRNA5 Antibody (Center) Blocking peptide - Background

The protein encoded by this gene is a nicotinicacetylcholine receptor subunit and a member of a superfamily ofligand-gated ion channels that mediate fast signal transmission atsynapses. These receptors are thought to be heteropentamers composed of separate but similar subunits. Defects in this genehave been linked to susceptibility to lung cancer type 2 (LNCR2).

## CHRNA5 Antibody (Center) Blocking peptide - References

Wessel, J., et al. Neuropsychopharmacology 35(12):2392-2402(2010)Erlich, P.M., et al. Hum. Genet. 128(5):491-499(2010)Shimada, M., et al. Hum. Genet. 128(4):433-441(2010)Falvella, F.S., et al. J. Natl. Cancer Inst. 102(17):1366-1370(2010)Li, M.D., et al. PLoS ONE 5 (8), E12183 (2010):